Maxim Group Maintains Buy on Health In Tech, Lowers Price Target to $3
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Maxim Group analyst Allen Klee maintains Health In Tech (NASDAQ:HIT) with a Buy and lowers the price target from $4 to $3.
Maxim Group analyst Allen Klee maintains Health In Tech (NASDAQ:HIT) with a Buy and lowers the price target from $4 to $3.